phase 2 trial raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-25. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
=== Awards received in the 2000s === COLACRO (Congreso Latinoamericano de Cromatografia) Merit Medal; Pittsburgh Analytical Chemistry Award; Eastern Analytical Symposium Award for Outstanding Achievements in the Fields of Analytical Chemistry; Tracy M. Sonneborn Award for Outstanding Research and Teaching, Indiana University; Dal Nogare Award in Chromatography; CaSSS (California Separation Science Society) Award for Excellence in Separation Science; Honorary Member of the Slovak Pharmaceutical Society; Foreign Member of the Learned Society of the Czech Republic (Czech Academy of Sciences); American Chemical Society Award in Analytical Chemistry; Jan Weber Prize and Medal, Slovak Pharmaceutical Society, Slovakia; Ralph N. Adams Award in Bioanalytical Chemistry.
WJ0679 is a small-molecule oxytocin receptor agonist and vasopressin receptor antagonist. It acts specifically as a very weak partial agonist of the oxytocin receptor (Ki = 422 nM; EC50Tooltip half-maximal effective concentration = 406 nM; EmaxTooltip maximal efficacy = 13%) and as an antagonist of the vasopressin V1A receptor (Ki = 105 nM; IC50Tooltip half-maximal inhibitory concentration = 2,203 nM), whereas no data were reported for the vasopressin V2 receptor. Despite its low activational efficacy at the oxytocin receptor, WJ0679 induces prosocial effects, including increased time spent in close physical contact and increased active social investigation, in rodents. The chemical synthesis of WJ0679 has been described. Along with its close analogue CA7, WJ0679 has the smallest chemical structure known for an oxytocin receptor agonist, with WJ0679 having about 60% of the molecular weight of LIT-001 and both WJ0679 and CA7 lacking LIT-001's tail component. Many analogues of WJ0679 and CA7 have been described. WJ0679 was first described in the scientific literature by a group including Michael Kassiou, Michael Bowen, Iain McGregor, and others at the University of Sydney in 2018. This group has founded a startup pharmaceutical company called Kinoxis Therapeutics and is developing small-molecule oxytocin-related drugs like KNX-100 and the KNX-200 series for potential medical use as of the 2020s.
Naturally occurring tellurium on Earth consists of eight isotopes: 120, 122-126, 128, 130. The heaviest two have been found to be radioactive: 128Te and 130Te undergo double beta decay with half-lives of, respectively, 7.7×1024 years (the longest half-life of all nuclides proven to be radioactive) and 7.9×1020 years. Artificial radioisotopes of tellurium are known, with atomic masses that range from 104 to 142, of which the most stable is 121Te with a half-life of 19.31 days. Several nuclear isomers have longer half-lives, the longest being 121mTe with a half-life of 164.7 days. The very long-lived radioisotopes 128Te and 130Te are the two most common isotopes of tellurium. Of elements with at least one stable isotope, only indium and rhenium likewise have a radioisotope in greater abundance than a stable one. It has been claimed that electron capture of 123Te was observed, but more recent measurements of the same team have disproved this. They have determined the half-life of 123Te to be longer than 9.2 × 1016 years (or 2 × 1015 years without any theoretical assumptions). Its observational stability presents one of only two apparent violations of the Mattauch isobar rule, the other involving 180mTa. 124Te is used as the starting material in the production of certain radionuclides by a cyclotron or other particle accelerator, such as iodine-123 and iodine-124. With the exception of beryllium, tellurium is the lightest element observed to have isotopes capable of undergoing alpha decay, with isotopes 104Te to 109Te being seen to undergo this mode of decay.
Some effects are dependent upon the route of administration, with intravenous use associated with the transmission of many disease such as hepatitis C, HIV/AIDS, and potential medical emergencies such as infection, thrombosis, or pseudoaneurysm, while inhalation may be associated with increased lower respiratory tract infection, lung cancer, and pathological restricting of lung tissue. Cocaine may also increase risk for autoimmune disease and damage nasal cartilage. Abuse of methamphetamine produces similar effects as well as marked degeneration of dopaminergic neurons, resulting in an increased risk for Parkinson's disease.
Sources: en.wikipedia.org
The witch doctor drinks a very small amount each time and knows well how many times he can sample the brew without losing his senses to properly conduct the ritual and lead the choir". Another report produced in 1737 by the missionary Pablo Maroni, describes the use of a psychoactive liana called ayahuasca for divination in the Napo River, Ecuador: "For divination, they use a beverage, some of white datura flowers, which they also call Campana due to its shape, and others from a vine commonly known as Ayahuasca, both highly effective at numbing the senses and even at taking one's life if taken in excess. They also occasionally use these substances for the treatment of common illnesses, especially headaches. So, the person who wants to divine drinks the chosen substance with certain rituals, and while deprived of their senses from the mouth downwards, to prevent the strength of the plant from harming them, they remain in this state for many hours and sometimes even two or three days until the effects run their course, and the intoxication subsides. After this, they reflect on what their imagination revealed, which occasionally remains with them for delirium. This is what they consider accomplished and propagate as an oracle." Latter reports were produced by Juan Magnin in 1740, describing ayahuasca use as a medicinal plant by the "Jivaroan" peoples (called ayahuessa) and by Franz Xaver Veigl in 1768, that reports about several "dangerous plants", including a bitter liana used for precognition and sorcery.
=== Effects in males === LH acts upon the Leydig cells of the testis and is regulated by gonadotropin-releasing hormone (GnRH). The Leydig cells produce testosterone under the control of LH. LH binds to LH receptors on the membrane surface of Leydig cells. Binding to this receptor causes an increase in cyclic adenosine monophosphate (cAMP), a secondary messenger, which allows cholesterol to translocate into the mitochondria. Within the mitochondria, cholesterol is converted to pregnenolone by CYP11A1. Pregnenolone is then converted to dehydroepiandrosterone (DHEA). DHEA is then converted to androstenedione by 3β-hydroxysteroid dehydrogenase (3β-HSD) and then finally converted to testosterone by 17β-hydroxysteroid dehydrogenase (HSD17B). The onset of puberty is controlled by two major hormones: FSH initiates spermatogenesis and LH signals the release of testosterone, an androgen that exerts both endocrine activity and intratesticular activity on spermatogenesis. LH is released from the pituitary gland, and is controlled by pulses of gonadotropin-releasing hormone. When bloodstream testosterone levels are low, the pituitary gland is stimulated to release LH. As the levels of testosterone increase, it will act on the pituitary through a negative feedback loop and inhibit the release of GnRH and LH consequently. Androgens (including testosterone and dihydrotestosterone) inhibit monoamine oxidase (MAO) in the pineal gland, leading to increased melatonin and reduced LH and FSH by melatonin-induced increase of gonadotropin-inhibitory hormone (GnIH) synthesis and secretion.
It typically appears in the form of a white or brown powder. Treatment of heroin addiction often includes behavioral therapy and medications. Medications can include buprenorphine, methadone, or naltrexone. A heroin overdose may be treated with naloxone. As of 2015, an estimated 17 million people use opiates non-medically, of which heroin is the most common, and opioid use resulted in an estimated 109 thousand to 129 thousand deaths in 2015. The total number of heroin users worldwide is believed to have increased in Africa, the Americas, and Asia between 2000 and 2015. In the United States, approximately 1.6 percent of people reported using heroin at some point in their lives and 0.4% of people aged 12 or older in 2021 reported using heroin in the past 12 months. When people die from overdosing on a drug, the drug is usually an opioid and often heroin. Heroin was first made by C. R. Alder Wright in 1874 from morphine, a natural product of the opium poppy. Internationally, heroin is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs, and it is generally illegal to make, possess, or sell without a license. About 448 tons of heroin were made in 2016. In 2015, Afghanistan produced about 66% of the world's opium. Illegal heroin is often mixed with other substances such as sugar, starch, caffeine, quinine, or other opioids like fentanyl.
MRI offers the greatest image resolution and can provide diagnostic information on presence of soft tissue infection or bone infection. Like ultrasound, MRI does not expose patients to radiation, however it is the slowest and most difficult to implement of all of these imaging methods. Laboratory studies: Serum prealbumin levels may be useful in evaluating nutrition status in patients with chronic wounds or at risk for developing chronic wounds. Elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) can confirm presence of an infection but alone are not diagnostic. Routine bloodwork such as a basic metabolic panel (BMP) or complete blood count (CBC) are not typically required but may be useful in select circumstances. Ankle-brachial index/toe-brachial index (ABI/TBI): These tests can be used to assess blood supply to the lower extremities and their results may affect management of lower extremity wounds such as venous/arterial ulcers, diabetic foot ulcers, or pressure ulcers.
The establishment is a modern, structured research institute composed of six laboratories dedicated to Virology, Parasitology, Bacteriology, Medical Entomology, Clinical Biology and Pathology, including a Research Center for animals and a data center. Each laboratory is made up of a dedicated director and staff, including students and international collaborators. Each laboratory has the basic equipment and the space necessary for optimal research. It is available to faculty, students, post-docs and staff from the periphery of the INRB. Due to the structure of the INRB, if sharing and access to individual laboratory equipment is required, access is granted at the request and approval of the directors of these laboratories. The INRB common area includes some major equipment. All collaborators and researchers have, upon request, access to several -80 freezers, liquid nitrogen tanks, centrifuges, water baths, tissue homogenizers, vortexes, incubators, agitators, and all laboratories have access to cold chain equipment such as dry shippers and portable freezers. The INRB was founded in 1984 and has been a World Health Organization collaborating centre since 2018. The INRB and the World Health Organization have worked closely together on research into the effectiveness of the ring vaccination strategy during the 2018 Kivu Ebola outbreak. The National Biomedical Research Institute (INRB) has eight dynamic departments, which participate in the institute's various missions, namely monitoring, research, and training.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.